Archived chat: last week in CRISPR — cancer, patents, and a dip in the market

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What’s included?

• Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
• Subscriber-only networking events and panel discussions across the country
• Monthly subscriber-only live chats with our reporters and experts in the field
• Discounted tickets to industry events and early-bird access to industry reports